Opinion: The money flowing into rare disease research simply isn’t enough to help the millions of people who need it. We’re at a point where smarter funding could completely change the game for these patients, but instead, investment continues to chase blockbuster drugs for common diseases rather than delivering deep societal good. Our priorities don’t match the size of the problem.
Key Takeaways
- Global investment in rare disease research hit about $15 billion in 2025, which is up 15% from 2023, almost all of it from private companies getting into gene therapies and chasing orphan drug status.
- Big wins in CRISPR-based gene editing and mRNA vaccine platforms are now being repurposed for rare genetic problems like cystic fibrosis and Huntington’s, with a few clinical trials expected to hit Phase 2 by the end of 2026.
- Governments in the EU and US are trying to help by sweetening the pot with more orphan drug incentives and creating special funding tracks, like the European Joint Programme on Rare Diseases, to make early research less of a financial gamble.
- It now costs over $1.5 billion on average to get a single rare disease drug through to approval, a huge barrier for any small biotech that hasn’t already landed major VC funding or a public-private deal.
* The “diagnostic odyssey” is still a massive problem. Patients are waiting an average of 4 to 7 years for the right diagnosis, which wastes critical time for treatment and keeps them out of research studies.
The world of rare disease research is a mix of brilliant science and maddeningly broken systems. You’ve got incredible advances in genomics and cell therapies giving people real hope, but then you look at where the money is actually going and it’s a mess, driven by market logic instead of patient need. After spending two decades watching how biomedical research gets funded, my take is simple: we’re not spending enough, and we’re not spending it smartly. There are around 7,000 rare diseases out there, affecting hundreds of millions of people, and our current approach just won’t get to them all. We get excited about a few big successes, but the financial engine behind it all is too conservative, too splintered, and obsessed with short-term wins.
The Double-Edged Sword of Orphan Drug Incentives
For decades, orphan drug designations have been the main reason big pharma has bothered with rare diseases at all. The incentives, things like years of market exclusivity, tax credits for the research, and waived FDA fees, were designed to make it financially viable to develop a drug for a tiny group of patients. And it worked. The Orphan Drug Act of 1983 in the US kicked off a boom in approvals that’s still going. A 2025 report from the IQVIA Institute for Human Data Science showed that over 60% of all new drugs approved in the past three years had an orphan designation. That’s brought treatments to people who used to have nothing.
The problem is, the system has created some warped results. That extended market exclusivity often leads to sky-high prices that patients and health systems can’t afford. Yes, development costs are high, the Tufts Center for the Study of Drug Development pegged the cost to bring a new rare disease drug to market at over $1.5 billion in 2024, but the final price tag is often way out of proportion. This affects the sustainability of the entire healthcare system. We’re seeing it with treatments for conditions like spinal muscular atrophy, where a single patient’s life-changing therapy can cost millions. The original law had good intentions, but now we’re in a situation where affordability is an afterthought. We need to start tying prices to actual results with value-based models, or maybe have different exclusivity periods depending on how risky the research was and how many people were suffering without a cure.
Breakthroughs on the Horizon: Gene Therapy and AI’s Role
Even with all the funding headaches, the science itself is moving at an incredible pace. Gene therapy isn’t just a concept anymore. It’s showing real results in a growing list of diseases. Take CRISPR-based gene editing. It’s moved out of the lab and into clinical trials for sickle cell anemia and some types of inherited blindness. A 2025 review in Nature Medicine counted over 50 gene editing trials happening or being planned around the world, which is a massive jump from just a few years ago. These treatments aim to fix the root genetic problem, offering the possibility of a one-time cure that changes everything for a patient.
On top of that, artificial intelligence is starting to change the game at every step. AI can chew through massive genomic datasets to find new disease targets, predict which drugs might work, or even find new uses for old drugs. For example, teams at the Broad Institute of MIT and Harvard (broadinstitute.org) are using AI to speed up the process of finding the genetic cause of ultra-rare diseases, cutting down that awful diagnostic wait for families. This is a huge deal for rare diseases where you have so few patients and so little data. I’ve seen AI platforms screen millions of compounds for a potential therapeutic effect in a weekend, a task that would take a human team years. It’s a completely different way of doing drug discovery.
The Funding Gap and the Call for Public-Private Teamwork
While private money from VCs and pharma floods into the late stages of drug development, there’s a huge funding gap for the early, risky, academic science where all the big ideas come from. That initial work is where the highest risk is, but it’s also where we make the fundamental discoveries that everything else is built on. Government agencies like the NIH in the US and the European Commission are supposed to cover this, but their budgets are always getting squeezed by politics, leading to unpredictable funding. That 2024 Milken Institute (milkeninstitute.org) report really laid it bare: private investment in rare disease therapies grew 18% in 2025, while public funding for the basic science behind it only went up 5%.
That imbalance means a lot of great ideas coming out of university labs just die. They can’t get the seed funding they need to even see if a concept is viable before a private company would ever look at it. We need a much bigger, more consistent financial commitment from governments to fill that valley of death. What’s also needed are better public-private partnerships. We need models where universities, patient groups, pharma companies, and government agencies all chip in to get things done, sharing data and risk. The Accelerating Medicines Partnership (AMP) program has already shown this can work in other diseases. We should be applying that same playbook to rare diseases to get more shots on goal. Without that kind of teamwork, we’re just leaving patients waiting for treatments that are stuck in a lab somewhere because of a funding shortfall.
Industry insiders sometimes argue that the market will sort this out, that the huge profits from one successful orphan drug will get plowed back into R&D for the next one. There’s a sliver of truth to that, but it’s a painfully slow and inefficient way to do science. Relying on market forces means ignoring our responsibility to tackle diseases that just don’t affect enough people to promise a billion-dollar payday. The human cost of that wait is staggering, measured in years of suffering for patients and families who just want a diagnosis, let alone a treatment. We have to be deliberate in our investment choices, not just wait for the market to hopefully get around to it.
A Call to Action for Cohesive Investment
The only way forward is a more coordinated investment plan for rare disease research. We have to keep tweaking orphan drug incentives so they drive real innovation without leading to prices that break the bank. We also have to dramatically increase public funding for the basic science that starts the whole process. And we need to build more formal public-private partnerships, like dedicated rare disease funds or consortiums, to make it easier to get a discovery from a lab bench to a patient’s bedside. The scientific tools like gene therapies and AI-driven drug discovery are ready to go. It’s the financial and collaborative structures that are broken and need fixing. If we don’t get a bolder, more coordinated investment strategy in place, all this scientific promise will stay just out of reach for the people who need it most.
What is a rare disease?
A rare disease, or orphan disease, is one that affects a small fraction of the population. The definition varies by country: in the US, it’s any disease affecting fewer than 200,000 people, while in the EU, the threshold is fewer than 1 in 2,000 people. Experts estimate there are between 7,000 and 10,000 distinct rare diseases, most of them genetic.
Why is rare disease research challenging?
It’s tough for several reasons. Small patient numbers make it hard to run clinical trials, and for many diseases, we don’t even understand the basic biology. Getting a correct diagnosis can take years. On top of that, the small market size offers little commercial incentive for drug companies, which results in a scarcity of available treatments and research funding.
How do orphan drug designations work?
They are basically a set of financial incentives to convince drug companies to develop treatments for rare diseases. To make it economically viable to pursue a drug for a small patient population, governments offer perks like market exclusivity for a number of years after approval (seven in the U.S., ten in the EU), tax credits on R&D costs, and help with the regulatory process.
What role does gene therapy play in rare disease treatment?
For rare diseases caused by a single faulty gene, gene therapy is a huge deal. The whole idea is to introduce, remove, or alter the genetic material inside a patient’s cells to fix the underlying problem. It offers the potential for a one-time treatment that could be a permanent cure which is a radical departure from managing symptoms for a lifetime.
Are there enough investments in rare disease research?
No, not really. While a lot of private money has been flowing into later-stage gene therapies, there’s a chronic shortage of funding for the early-stage, basic science that happens in academic labs. Most experts agree that the total investment, especially from public sources, is way too low to tackle the thousands of rare diseases that still have no treatment at all.
